Investment Focus Summary

Focus

Healthcare companies pursuing innovative, breakthrough science that will impact patient care and be reimbursable

Create new sources of growth for GSK technologies and know-how

Geography

Global, especially North America and Europe

Board Role

Board of directors seat or observer rights, consistent with ownership amount

Syndication

Lead or take an active syndicate role in our investments

Rights

No product rights or options are requested in our investment terms



Fund Fundamentals (on RHS)

LPs

Structured as an independent subsidiary of GSK, our sole investor

Direct to report to GSK Chairman of R&D

Function

Corporate function that supports GSK's entire business (R&D, Vaccines and Consumer Health)

Investment Process

Final Investment committee of three (CEO/Chairman of R&D, GSK and President, SR One)

Portfolio

Approximately 25 private and public companies

Capital

$600MM invested since inception in 1985

Firewall

We maintain a strict firewall with GSK regarding any confidential information

Back
 
Aileron    Alios    Locus Pharmaceuticals